𝐕𝐀𝐂𝐂𝐈𝐍𝐄 𝐒𝐄𝐑𝐈𝐄𝐒: 𝐏𝐎𝐒𝐓 𝟐 𝐒𝐨, 𝐰𝐡𝐚𝐭’𝐬 𝐭𝐡𝐞 𝐭𝐢𝐦𝐞𝐥𝐢𝐧𝐞 𝐟𝐨𝐫 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐝𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧? 𝐖𝐡𝐞𝐧 𝐰𝐢𝐥𝐥 𝐈 𝐠𝐞𝐭 𝐨𝐧𝐞? 𝐀𝐧𝐝, 𝐝𝐢𝐝 𝐲𝐨𝐮 𝐡𝐞𝐚𝐫 𝐚𝐛𝐨𝐮𝐭 𝐌𝐨𝐝𝐞𝐫𝐧𝐚?

After the first post this morning with a strong dose of reality, how ’bout some good news with a strong dose of the future!

𝐏𝐈𝐂𝐓𝐔𝐑𝐄 𝟏 – Let’s talk about the distribution process. Operation Warp Speed is leveraging existing partnerships, networks, and processes to make this huge endeavor work. I heard Dr. Fauci call this “all hands on deck”. Yep! Major airlines are on board (I saw this morning where Pfizer vaccines were being flown on United to the US), Fed Ex / UPS are on board, and I’m sure 10,000 other logistical players are on board too. The process shown in Picture 1 feels a bit like a “yeah buddy!” (like a good Texan) to me. I’m super proud of science and equally in awe of smart, strategic, and logistically-minded people who can figure all of this out with efficiency and safety. Clap.Your.Hands, web-peeps. This is some awesome-sauce right here.

𝐏𝐈𝐂𝐓𝐔𝐑𝐄 𝟐 – So, when will I get mine? It depends on your state. But, here’s the general timeline. Note, this could change depending on other vaccine candidates that complete the Phase 3 trials (so, that means we have more doses quicker) and other factors. But, so far we have Pfizer and Moderna that have submitted for Emergency Authorization Use (EAU) and the FDA will meet to discuss all.the.data December 10th (Pfizer) and around December 17th (Moderna). EAU can then happen as quick as 24-48 hours later. “Yeah buddy!” again, friends.

𝐏𝐈𝐂𝐓𝐔𝐑𝐄 𝟑 – Speaking of Moderna: Presenting the Moderna vaccine final analysis: 👏👏 Moderna announced the final results of the 30,000 person trial today. Here’s the highlights/woo-hoos:

1. The Moderna vaccine had 100% efficacy (y’all, 100% is a big deal) against SEVERE disease. There were 0 cases (zilch, nada, nope, none) severe COVID-19 cases in the vaccine group and 30 in the placebo group. THIS IS THE BEST finding to me.

2. There were 196 symptomatic cases of COVID-19: 11 in the vaccine group and 185 in the placebo group. That translates to (drum roll please….) an efficacy of 94.1%. This is similar to the 95% efficacy from Pfizer.

3. The trial (called the Phase 3 COVE Study) includes (these are direct quotes from the press release): – more than 7,000 Americans over the age of 65. – more than 5,000 Americans who are under the age of 65 but have high-risk chronic diseases that put them at increased risk of severe COVID-19, such as diabetes, severe obesity and cardiac disease. These medically high-risk groups represent 42% of the total participants in the Phase 3 COVE study. – communities that have historically been under-represented in clinical research and have been disproportionately impacted by COVID-19. The study includes more than 11,000 participants from communities of color, representing 37% of the study population, which is similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or LatinX, and more than 3,000 participants who identify as Black or African American.

All good signs, web-peeps. Stay strong in your masking, distancing, hand-washing, avoiding crowds, etc. In the vaccine series, we’ll talk about what mRNA technology is (and isn’t), what the roll-out looks like for all of us, side-effects, and some myth-busters.

𝐔𝐧𝐭𝐢𝐥 𝐭𝐡𝐞𝐧, 𝐰𝐞 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞 𝐨𝐧. 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐢𝐬 𝐠𝐞𝐭𝐭𝐢𝐧𝐠 𝐥𝐨𝐮𝐝𝐞𝐫!

Here’s Post 1 from the Vaccine Series: https://tinyurl.com/y27txvro

-Friendly neighbor epidemiologist


Picture 1 – https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html

Picture 2- https://www.businessinsider.com/coronavirus-vaccine-timeline-when-will-they-get-authorized-shots-start-2020-11

Picture 3 – https://www.nytimes.com/2020/11/30/health/covid-vaccine-moderna.html?campaign_id=60&instance_id=0&regi_id=75315945&segment_id=45667&user_id=ff186e8ac11fc897341452025166daf3

Picture 3 from article above: Cody O’Loughlin for The New York Times

Moderna press release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study

Leave a Reply